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S U M M A R Y
Objectives: Bordetella pertussis continues to circulate even in countries with good childhood vaccination
coverage. This study was undertaken to deﬁne the relationship between documented disease and the
clinical criteria proposed by the World Health Organization (WHO).
Methods: Nasopharyngeal swab samples were collected from previously healthy 6–14-year-old school
children in Tehran, presenting with persistent cough of at least 2- week duration. Specimens were
examined for Bordetella pertussis and Bordetella parapertussis by culture and polymerase chain reaction
(PCR).
Results: Out of 6601 students, 328 (5.0%) had been coughing for at least 2 weeks. Of these children with
cough, 182 (55.5%) experienced whooping, 194 (59.1%) suffered a paroxysmal cough, and 73 (22.3%) had
post-tussive vomiting. Twenty-one (6.4%) samples tested positive for B. pertussis and six (1.8%) for B.
parapertussis by PCR. Culture of four (1.2%) specimens was positive for B. pertussis. In comparison to PCR,
the sensitivity and the speciﬁcity of the WHO clinical criteria (year 2000) were 95.2% and 15.0%,
respectively.
Conclusions: Pertussis remains one of the etiologies of prolonged cough, even in communities with high
immunization in children. The speciﬁcity of the WHO criteria is low in diagnosing pertussis compared
with PCR.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Whooping cough is a highly contagious disease; despite the
implementation of large-scale immunization programs, reported
cases of pertussis have increased in many populations with high
immunization in children during the last decade.1,2 This has been
accompanied by a change in the epidemiology of the disease,
characterized by a signiﬁcant increase in pertussis among
adolescents and adults, who constitute the main source of
infection for infants.1
The World Health Organization (WHO) reports that there are
currently around 48.5million annual cases of pertussis worldwide,
with as many as 295 000 fatalities each year.3 Although pertussis
may occur at any age, most cases of serious disease and the
majority of fatalities are observed in early infancy, particularly in
preterm and non-immunized infants.3
In spite of a more than 95% coverage rate for the third dose of
pertussis vaccine, a resurgence of pertussis is suspected in Iran;* Corresponding author.
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of a lack of precise surveillance data. The pertussis vaccination
program in Iran includes three doses of a whole-cell pertussis
vaccine together with diphtheria and tetanus toxoid (DTwP) at
months 2, 4, and 6 of life and then two additional booster doses at
1.5 and 4–6 years. The Iranian Centers for Disease Control reported
that the incidence of Bordetella pertussis in Iran was 0.5 cases per
100 000 population in 2008 – higher than the previous year, 0.19
cases per 100 000 population.4 It has to be considered that this
variation may be partly due to the cyclic pattern of disease
distribution, with a peak incidence every 3–5 years. The low
reported incidence in Iran may be due to inefﬁcient surveillance
and also because of the common misconception of Iranian health
workers that pertussis has been eradicated by the high vaccination
coverage in our country.
The clinical diagnosis of pertussis is complicated by the
heterogeneity in disease expression, modiﬁcation of disease by
immunization, mixed infections, and a low index of suspicion
among many physicians.1 It is recognized that a key part of
achieving disease control is the revision of case deﬁnitions and the
utilization of the latest laboratory techniques for accurate
diagnosis. Deﬁnite diagnosis depends on isolation of B. pertussisses. Published by Elsevier Ltd. All rights reserved.
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chain reaction (PCR) or through positive paired serology. It has
been demonstrated that PCR has greater sensitivity than culture
and is helpful especially in diagnosing mild cases and in patients
who have received antibiotics or are studied late in the course of
illness.5
In 1997, the US Centers for Disease Control and Prevention
(CDC) proposed deﬁnitions for pertussis. Accordingly a ‘clinical
case’ was a patient with cough of 14 days and at least one of the
symptoms of paroxysmal cough, whoop, or post-tussive vomiting
and a ‘conﬁrmed case’ was one with positive laboratory ﬁndings
either by culture or PCR or a patient with a clinical case deﬁnition
and history of contact with a person with laboratory-conﬁrmed
pertussis.1
In 2003 the WHO speciﬁed the deﬁnition of ‘clinical case’
according to deﬁnite criteria, i.e., a case diagnosed as pertussis by a
physician or whomeets the clinical case deﬁnition proposed by the
CDCwithout other apparent cause.6 According to theWHO criteria,
a ‘clinically conﬁrmed case’ is a case that meets the clinical case
deﬁnition but is not laboratory-conﬁrmed and a ‘laboratory
conﬁrmed case’ is one that meets the clinical case deﬁnition and
is laboratory-conﬁrmed according to culture, PCR, or positive
paired serology.6
This study examined the sensitivity and the speciﬁcity of the
WHO clinical criteria in laboratory conﬁrmed cases of pertussis in
whom a deﬁnite diagnosis was made by means of positive PCR or
positive culture for B. pertussis.
There has been no study to determine the incidence of pertussis
in Iranian children and adolescents. This investigation was a
population-based study to deﬁne the incidence of the disease in 6–
14-year-old Iranian school children and to determine the
frequency of symptoms in conﬁrmed cases. The selection of this
age group has two advantages: ﬁrst, nearly all the population in
this age range is accessible in schools and second, middle school-
aged children encompass the group in which waning vaccine
efﬁcacy is predicted and elementary school-aged children are
presumed to be protected against pertussis because of vaccine-
induced immunity.
2. Materials and methods
The study was carried out from September 2007 to November
2008. After obtaining permission from the health and education
ministries, the study team distributed questionnaires to school
principals to be distributed to parents. These forms included
queries about relevant demographic variables and also questions
about clinical manifestations of pertussis viz. duration of cough,
presence of coughing paroxysms, whooping and vomiting after
cough, and cyanosis, and history of vaccination, taking medication,
or the presence of any related diseases. After obtaining parental
consent, all children aged between 6 and 14 years with a cough of
2-week duration ormore, butwithout any documented underlying
diseases, were selected for further investigation. Posterior
nasopharyngeal samples were obtained and symptoms rechecked
once more by telephone interview with the parents. A team
consisting of a subspecialist infectious diseases pediatrician and
three trained laboratory technicians were responsible for obtain-
ing the specimens. Children with an immune deﬁciency or
congenital cardiac or chronic lung disease (asthma, cystic ﬁbrosis,
gastroesophageal reﬂux), and also those with an audible heart
murmur or respiratory wheezing were excluded from the study.
The population under investigation consisted of the school
students in district 9 of the Tehran Board of Education; 20 out of
136 schools in that district were chosen randomly – nine were
primary schools (grades 1–5) and 11 intermediate (grades 6–8). A
total of 6601 children were studied in these schools. Samples weretaken with two ﬂexible Dacron swabs from the posterior
nasopharynx (PNP) of the selected children. The swabs were
inoculated onto the slant surface of Regan–Lowe medium and the
lids of the medium tubes were closed tightly. The specimens were
kept at temperatures of 0–4 8C and sent to the laboratory within
6 h. One swab from every specimen was subcultured on fresh
Bordet–Gengou medium containing sheep blood and cephalexin
40%, and incubated at 37 8C with 80% humidity for 3–10 days until
the colonies emerged. If no growth was seen on Bordet–Gengou
medium after 10 days, the sample was considered negative for
culture. For the PCR, the slant surfaces of Regan–Lowe medium of
the other series of swabs was washed with buffer solution. The
washed off solution was transmitted to micro-tubes for PCR
preservation. Extraction of DNA from PNP specimens was
performed using the Sinnagen (Tehran, Iran) extraction kit. The
primers for B. pertussis and Bordetella parapertussis were supplied
by MWG Company (Germany). Detection of B. pertussis was based
on the ampliﬁcation of a section of the IS481. Ampliﬁcation of the
sequence IS1001 was used for the detection of B. parapertussis
(8.1ml of primer for preparation of 50 ml work stock). The
sequences of the oligonucleotide primers were identical to those
listed in the report by Ko¨sters et al.7 Positive controls were B.
pertussis ATCC 9797 and B. parapertussis ATCC 9305 from the
Pasteur Institute of Iran.
3. Statistical analysis
According to the study sampling (random cluster analysis
sampling), we deﬁned the schools as primary sampling units and
ran survey data analysis in Stata 9.1 (Stata Corp., College Station,
TX, USA). Standard errors were computed by linear model and a
95% conﬁdence interval (95% CI) reported for each proportion. To
evaluate the effect of certain variables on laboratory results,
logistic regression (standard errors were adjusted for cluster of
schools) was used. Since the duration of clinical symptoms is not
usually more than 6–8 weeks and specimens were obtained from
children only at the ﬁrst visit (i.e., we did not request information
on children who developed a cough after the ﬁrst visit to obtain a
specimen), the calculated frequency could be considered as
incidence.
4. Results
The total number of students in the selected schools was 6601.
Three-hundred twenty-eight children (5.0%) had experienced a
persistent cough for at least 2 weeks. Study subjects were aged
between 6 and 14 years (mean 11 years). By age group, 93 (28.3%)
were aged 6–8 years, 81 (24.7%) were aged 9–11 years, and 154
(47.0%) were aged 12–14 years; 180 (54.9%) were male.
Three hundred and twenty-seven children were fully vaccinat-
ed against pertussis; only one had received fewer than three doses
of the DTwP vaccine. Antibiotics had been prescribed for 190
children (58.3%); only 1.8% of these 190 children had received
macrolides or trimethoprim–sulfamethoxazole.
The mean duration of cough was 20 days. Of the 328 children
with 2 weeks of coughing, 194 (59.1%; 95% CI 48.6–69.7) had a
paroxysmal cough, 182 (55.5%; 95% CI 46.1–64.9) had whooping,
and 73 (22.3%; 95% CI 16.–27.9) had post-tussive vomiting (Table
1). Twenty-one of 328 (6.4%; 95% CI 3.11–9.69) children with a
persistent cough had a positive PCR test for B. pertussis and six of
328 (1.8%; 95% CI 0–3.62) for B. parapertussis. B. pertussis was
detected in culture in four of 328 specimens (1.2%; 95% CI 0–2.74),
i.e., all culture-positive cases were PCR-positive. Not a single
colony of B. parapertussis was found on culture.
The estimated incidence of B. pertussis in this age group, i.e., the
frequency of cases with a positive PCR for B. pertussis, was 318
Table 1
Clinical characteristics of patients with and without laboratory evidence of
Bordetella pertussis infection
Characteristic Evidence of
pertussis infection
(n=21)
No evidence of
pertussis infection
(n=307)
Duration of cough, days
Mean SD 48.674.4 29.942.4
Median, range 30 (14–360) 20 (14–360)
Whoop 15/21 (71.4%) 167/307 (54.4%)
Paroxysms 17/21 (81.0%) 177/307 (57.7%)
Post-tussive vomiting 13/21 (61.9%) 60/307 (19.5%)
WHO clinical criteriaa 20/21 (95.2%) 261/307 (85.0%)
SD, standard deviation; WHO, World Health Organization.
a Deﬁned as cough 14 days with either paroxysm of cough, inspiratory whoop,
or post-tussive vomiting without other apparent causes.
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per 100 000 population for B. parapertussis. The results of PCR and
culture for B. pertussis were in agreement in 94.9% of cases (either
both positive or both negative); theywere not in agreement in 5.1%
of cases viz. PCR was positive and culture negative. The Kappa
agreement was 0.31 (p < 0.001). Of those with a persistent cough,
3.2% (3/93) aged 6–8 years, 1.2% (1/81) aged 9–11 years, and 11.0%
(17/154) aged 12–14 years had a PCR positive for B. pertussis. The
frequency of cases, as diagnosed by a positive PCR, increased
signiﬁcantly with age (b = 0.26, p = 0.02), but this relationship did
not persist for parapertussis PCR (b = 0.02, p = 0.92). Two hundred
and eighty-ﬁve children had a cough for 2–6 weeks; 5.3% of these
had a positive PCR. For those who had been coughing for6 weeks
this ﬁgure was 14% (p = 0.04).
Laboratory ﬁndings in children presenting with the WHO
criteria of pertussis are given in Table 1.
According to these data, if PCR is considered the gold standard
for the diagnosis of B. pertussis, the sensitivity of the WHO criteria
(as given in the year 2000) is 95.2% (20/21). The speciﬁcity in this
population with 2 weeks of cough is 15.0% (Table 2).
The signiﬁcance of proposed symptoms for predicting con-
ﬁrmed pertussis is shown in Table 3.Table 2
Sensitivity and speciﬁcity of the WHO clinical criteria in relation to pertussis
nasopharyngeal PCR
Sensitivity Speciﬁcity
Cough  2 weeks + clinical; at least
one WHO criterion
95.2 15.0
Cough  2 weeks +whoop 71.4 45.6
Cough  2 weeks +post-tussive emesis 61.9 80.5
Cough  2 weeks +paroxysms 81.0 42.3
Cough  2 weeks + clinical; at least
two WHO criteria
81.0 60.3
Cough  2 weeks + clinical; at least
three WHO criteria
9.5 91.2
WHO, World Health Organization; PCR, polymerase chain reaction.
Table 3
The signiﬁcance of proposed symptoms for predicting conﬁrmed pertussis
Symptom Frequency of PCR
positives (n=21)
OR p-Value
Cough Positive 17 (8.8%) 3.12 0.08
Negative 4 (3.0%)
Whoop Positive 15 (8.2%) 2.10 0.11
Negative 6 (4.1%)
Vomiting Positive 13 (17.8%) 6.69 0.001
Negative 8 (3.1%)5. Discussion
In our subjects with persistent cough, 59.1% had paroxysms,
55.5% had whooping, and 22.3% had post-tussive vomiting, while
the ﬁgures from a study in adolescents inMassachusetts were 83%,
30%, and 45%, respectively; both studies show paroxysm as the
most common symptom.8 In our study emesis was the least
common ﬁnding.
In a hospital-based study in France, Baron et al.9 deﬁned index
and contact cases of pertussis conﬁrmed by culture and/or serology
in children or their contacts; paroxysms were seen in 84% of cases,
60% had vomiting, and 31% had whoop.9
In our study 95% of culture- or PCR-conﬁrmed cases met the
WHO clinical criteria. Moreover, the frequency of positive PCR
among those who had vomiting was higher than among students
with paroxysmal cough or whoop, i.e., 17.8%, 8.8%, and 8.2%,
respectively. The duration of cough was longer in children with a
positive PCR than in those with a negative PCR (49 days vs. 30
days). Senzilet et al.10 found similar results in adolescents and
adults 12 years old. The patients with laboratory evidence of
pertussis had a signiﬁcantly longer duration of cough and post-
tussive vomiting than patients without such laboratory conﬁrma-
tion (56 days vs. 46 days and 45.5% vs. 28.5%, respectively).10
According to our data, there were 20 positive PCRs for B.
pertussis in 281 children with cough for 2 weeks and at least one
symptom of paroxysmal cough, post-tussive emesis, or whooping.
If we take a positive PCR as the gold standard for the diagnosis of B.
pertussis, the sensitivity and speciﬁcity of the WHO criteria are
95.2% (20/21) and 15.0% (46/307), respectively.
Cherry et al.1 claimed that although previous surveys had
shown a deﬁnition of at least 14 days of cough to be both sensitive
(84–92%) and speciﬁc (63–90%) for monitoring outbreaks and
detecting contacts of culture-positive cases, it was not useful in
non-outbreak illness because of the low speciﬁcity; only 51% of
children who had cough 14 days with at least one of the WHO
criteria showed laboratory evidence of pertussis or parapertussis
infection (based on concurrentWHO criteria). These children were
evaluated stringently with repeated PCRs, culture, and paired
serology in order to reduce false-negative cases.11
Bamberger et al.12 showed that 76% of unvaccinated, 39% of
recently vaccinated, and 40% of post-vaccinated children with a
positive PCR did not meet the CDC diagnostic criteria for B.
pertussis; the conclusionwas that clinical criteria had no signiﬁcant
association with infection in recently vaccinated children.12
After examining anti-pertussis toxin immunoglobulin levels in
both symptomatic and asymptomatic participants, Cagney et al.13
reported that only a third of coughing illnesses due to pertussis in
Australian students met the CDC clinical case deﬁnition. They
estimated the incidence of the disease according to the CDC clinical
case deﬁnition to be 1587 cases per 100 000 in 12–14-year-old
children, much higher than the ﬁgures reported by the CDC.13
Gilberg et al.14 measured the frequency of B. pertussis in adults
with a duration of cough of 7–31 days. They concluded that 79% of
the culture-, PCR-, or serology-conﬁrmed cases met the WHO
criteria and that 89% met the CDC criteria. However, 83% of
patients with no evidence of pertussis also fulﬁlled these criteria,
indicating that the speciﬁcity of these deﬁnitions is low for
diagnosis in adults and that laboratory conﬁrmation is essential.14
In our study, although 95.2% of the conﬁrmed cases met the
WHO criteria, 93% of those without laboratory evidence of
pertussis also had these manifestations. If we diagnosed all
children who fulﬁlled the WHO clinical criteria for pertussis as
actually having the disease, then the estimated incidence of
pertussis in the school-aged childrenwould jump to 4257 cases per
100 000 population, an unacceptably high ﬁgure. Therefore it is
appropriate to indicate that the WHO criteria have a low
R.M. Ghanaie et al. / International Journal of Infectious Diseases 14 (2010) e1072–e1075 e1075speciﬁcity. It has to bementioned that there is a lack of consistency
from parents over case deﬁnitions based on subjective symptoms
such aswhooping and duration of cough. Thismay explain the high
frequency of whooping found in our research.
In order to increase the speciﬁcity, stricter criteria should be
used for diagnosis, such as cough of more than 3-week duration
and the inclusion of at least two or three clinical symptoms as a
prerequisite. The sensitivity and speciﬁcity for each of these
methods, except for the 3-week cough,weremeasured in our study
(Table 2). Improvement in speciﬁcity was achieved at the cost of
reduced sensitivity.
In 1988, Patriarca et al.11 showed that the presence of any single
acute respiratory symptom such as cough, coryza, nasal conges-
tion, or sore throat, was 100% sensitive but totally non-speciﬁc in
identifying patients with pertussis. If cough were considered a
prerequisite, it would increase the speciﬁcity of diagnosis to 28%,
with only a negligible change in sensitivity. When duration of
cough for 14 days or more was also included in the deﬁnition,
speciﬁcity rose signiﬁcantly to 63%, with only a modest decline in
sensitivity (to 84%). Deﬁnitions requiring paroxysmal cough
increased the speciﬁcity of diagnosis to 83%, but were accompa-
nied by a large reduction in sensitivity (52%).11
6. Conclusions
Even in countries where pertussis vaccination coverage for
children has been higher than 95% for several years, like Iran,
pertussis should be considered as one of the etiologies of prolonged
cough. The epidemiology of the disease in Iran is similar to that in
other countries which have already started to introduce booster
doses in the older age groups. It appears that it is time to consider
adolescent and adult immunization programs for pertussis.
Paroxysmwas themost common symptomand emesis the least
common symptom in our study. The frequency of positive PCR
among those who had vomitingwas higher than among those with
paroxysmal cough or whoop. The duration of coughing was longer
in children with a positive PCR than in those with a negative PCR.
The WHO clinical criteria are subjective and have a low
speciﬁcity. So in addition to clinical deﬁnitions presented by the
CDC and WHO, rapid, easy-to-use, inexpensive, and standardized
laboratory tests need to be available and widely implemented.
Besides improvements in national surveillance, comprehensive
population-based studies in different age groups are required. It is
necessary to increase awareness in the medical community about
adolescent and adult disease. An increased clinical suspicion of
infection and more sensitive laboratory diagnostic methods are
needed to assess the true incidence of pertussis in very young
infants, older adolescents, and those who have been vaccinated.The efﬁcacy of our vaccines needs to be evaluated, since
according to the age atwhich our booster dose is given and the high
vaccine coverage rate we would expect to have immunity to
pertussis at least in elementary school-aged children.
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